[
  {
    "ts": null,
    "headline": "Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View",
    "summary": "THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.",
    "url": "https://finnhub.io/api/news?id=b3186977b274aa015103ac1494352404a13ff6ba66b749503c2cda224399998f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753205400,
      "headline": "Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View",
      "id": 136034054,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.",
      "url": "https://finnhub.io/api/news?id=b3186977b274aa015103ac1494352404a13ff6ba66b749503c2cda224399998f"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains",
    "summary": "Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=549784c261e37b18608d7cd1bc9e7c1d105d7555302a877a94517e811c542366",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753202040,
      "headline": "Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains",
      "id": 136042291,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=549784c261e37b18608d7cd1bc9e7c1d105d7555302a877a94517e811c542366"
    }
  },
  {
    "ts": null,
    "headline": "NVST or ABT: Which Is the Better Value Stock Right Now?",
    "summary": "NVST vs. ABT: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=c89d610957a64859cdb22665ac6be6d1c29294beedbf97150feb865805d8683e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753198802,
      "headline": "NVST or ABT: Which Is the Better Value Stock Right Now?",
      "id": 136033450,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "NVST vs. ABT: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=c89d610957a64859cdb22665ac6be6d1c29294beedbf97150feb865805d8683e"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend Stocks With 100+ Years of History and Sky-High Growth",
    "summary": "These three century-old companies boast strong buy ratings, 50%+ dividend growth, and rock-solid fundamentals—ideal picks for long-term income investors.",
    "url": "https://finnhub.io/api/news?id=1fb4da305266a5f3b878cb9c8f3717fd1fbf6e0bf2a31dd98cb980f6a65e87c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753189202,
      "headline": "3 Dividend Stocks With 100+ Years of History and Sky-High Growth",
      "id": 136031308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "These three century-old companies boast strong buy ratings, 50%+ dividend growth, and rock-solid fundamentals—ideal picks for long-term income investors.",
      "url": "https://finnhub.io/api/news?id=1fb4da305266a5f3b878cb9c8f3717fd1fbf6e0bf2a31dd98cb980f6a65e87c6"
    }
  },
  {
    "ts": null,
    "headline": "Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?",
    "summary": "HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.",
    "url": "https://finnhub.io/api/news?id=7adb5452acd9c58189ec1acc4b22bd0da06d15735960023c22b5f560aa0116e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753187520,
      "headline": "Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?",
      "id": 136033451,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.",
      "url": "https://finnhub.io/api/news?id=7adb5452acd9c58189ec1acc4b22bd0da06d15735960023c22b5f560aa0116e0"
    }
  },
  {
    "ts": null,
    "headline": "Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales",
    "summary": "Company Continues to Strengthen Organizational Infrastructure with Success-Driven Medical Device Veteran Christina Bailey, VP of Sales, Microbot Medical Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales. A two-time",
    "url": "https://finnhub.io/api/news?id=3913414a97d2f81a802e68f51e94848b3a991eb8513dc5c7fa582fe47fab9eae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753187400,
      "headline": "Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales",
      "id": 136031427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Company Continues to Strengthen Organizational Infrastructure with Success-Driven Medical Device Veteran Christina Bailey, VP of Sales, Microbot Medical Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales. A two-time",
      "url": "https://finnhub.io/api/news?id=3913414a97d2f81a802e68f51e94848b3a991eb8513dc5c7fa582fe47fab9eae"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Kings: July 2025",
    "summary": "Discover why 14 Dividend Kings outperform the S&P 500 in 2025.",
    "url": "https://finnhub.io/api/news?id=0abfb9a06bfcdd22331e819cff2f63c95a0a2e603f074263e23c8ab514d9f843",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753176661,
      "headline": "Best Dividend Kings: July 2025",
      "id": 136031024,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158691690/image_2158691690.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Discover why 14 Dividend Kings outperform the S&P 500 in 2025.",
      "url": "https://finnhub.io/api/news?id=0abfb9a06bfcdd22331e819cff2f63c95a0a2e603f074263e23c8ab514d9f843"
    }
  }
]